Carbetocin
From Wikipedia, the free encyclopedia
 |
|
|
Carbetocin
|
|
| Systematic (IUPAC) name | |
| (2S)-1-[(3S,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]- 9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15- [(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17- pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane- 3-carbonyl]-N-[(1S)-1-(carbamoylmethylcarbamoyl)- 3-methyl-butyl]pyrrolidine-2-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | H01 |
| PubChem | |
| Chemical data | |
| Formula | C45H69N11O12S |
| Mol. mass | 988.162 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 80% (IM) |
| Metabolism | ? |
| Half life | 40 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous, intramuscular |
Carbetocin (INN) is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.
Carbetocin is available in Canada and the United Kingdom, but not in the United States.
[edit] See also
[edit] External links
- Carbetocin - drugs.com
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
